WHO ICTRP trial
TACE + vitamin K treatment
JPRN-jRCTs051180115 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCTs051180115 |
|---|---|
| Public title | TACE + vitamin K treatment |
| Scientific title | Efficacy and safety of TACE and vitamin K combination treatment against hepatocellular carcinoma-Open label, randomized, phase 2 study - TACEVK |
| Primary sponsor | Haruna Yoshimichi |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Conditions | Hepatocellular carcinoma (HCC) |
| Interventions | daily dosing of vitamin K2(45mg) since one day before TACE to 28 days after |
| Registration date | Nov 3, 2019 |
| Target size | 200 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: